Axon Neuroscience SE   Report issue

For profit Phase 2
Founded: Larnaca Cyprus (1999)
Status: Left NME R&D (2022)

Organization Overview

First Clinical Trial
2013
NCT01850238
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2017

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 2 Trials (1)

aadvac1 (4 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Alzheimer Disease (Phase 2)

Aphasia (Phase 1)

Aphasia, Broca (Phase 1)

Aphasia, Primary Progressive (Phase 1)

Frontotemporal Dementia (Phase 1)

Pick Disease of the Brain (Phase 1)

Primary Progressive Nonfluent Aphasia (Phase 1)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 4
  • # of Trial APIs: 1